158 related articles for article (PubMed ID: 9383464)
1. Molecular design and biological activity of potent and selective protein kinase inhibitors related to balanol.
Koide K; Bunnage ME; Gomez Paloma L; Kanter JR; Taylor SS; Brunton LL; Nicolaou KC
Chem Biol; 1995 Sep; 2(9):601-8. PubMed ID: 9383464
[TBL] [Abstract][Full Text] [Related]
2. Exploration of charge states of balanol analogues acting as ATP-competitive inhibitors in kinases.
Hardianto A; Yusuf M; Liu F; Ranganathan S
BMC Bioinformatics; 2017 Dec; 18(Suppl 16):572. PubMed ID: 29297286
[TBL] [Abstract][Full Text] [Related]
3. Differential and selective inhibition of protein kinase A and protein kinase C in intact cells by balanol congeners.
Gustafsson AB; Brunton LL
Mol Pharmacol; 1999 Aug; 56(2):377-82. PubMed ID: 10419557
[TBL] [Abstract][Full Text] [Related]
4. Balanol analogues probe specificity determinants and the conformational malleability of the cyclic 3',5'-adenosine monophosphate-dependent protein kinase catalytic subunit.
Akamine P; Madhusudan ; Brunton LL; Ou HD; Canaves JM; Xuong NH; Taylor SS
Biochemistry; 2004 Jan; 43(1):85-96. PubMed ID: 14705934
[TBL] [Abstract][Full Text] [Related]
5. The Protein kinase inhibitor balanol: structure-activity relationships and structure-based computational studies.
Pande V; Ramos MJ; Gago F
Anticancer Agents Med Chem; 2008 Aug; 8(6):638-45. PubMed ID: 18690827
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A.
Defauw JM; Murphy MM; Jagdmann GE; Hu H; Lampe JW; Hollinshead SP; Mitchell TJ; Crane HM; Heerding JM; Mendoza JS; Davis JE; Darges JW; Hubbard FR; Hall SE
J Med Chem; 1996 Dec; 39(26):5215-27. PubMed ID: 8978850
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and protein kinase inhibitory activity of balanol analogues with modified benzophenone subunits.
Lampe JW; Biggers CK; Defauw JM; Foglesong RJ; Hall SE; Heerding JM; Hollinshead SP; Hu H; Hughes PF; Jagdmann GE; Johnson MG; Lai YS; Lowden CT; Lynch MP; Mendoza JS; Murphy MM; Wilson JW; Ballas LM; Carter K; Darges JW; Davis JE; Hubbard FR; Stamper ML
J Med Chem; 2002 Jun; 45(12):2624-43. PubMed ID: 12036372
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of protein kinases by balanol: specificity within the serine/threonine protein kinase subfamily.
Setyawan J; Koide K; Diller TC; Bunnage ME; Taylor SS; Nicolaou KC; Brunton LL
Mol Pharmacol; 1999 Aug; 56(2):370-6. PubMed ID: 10419556
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and protein kinase C inhibitory activities of balanol analogs with replacement of the perhydroazepine moiety.
Lai YS; Mendoza JS; Jagdmann GE; Menaldino DS; Biggers CK; Heerding JM; Wilson JW; Hall SE; Jiang JB; Janzen WP; Ballas LM
J Med Chem; 1997 Jan; 40(2):226-35. PubMed ID: 9003521
[TBL] [Abstract][Full Text] [Related]
10. Diverse dynamics features of novel protein kinase C (PKC) isozymes determine the selectivity of a fluorinated balanol analogue for PKCε.
Hardianto A; Khanna V; Liu F; Ranganathan S
BMC Bioinformatics; 2019 Feb; 19(Suppl 13):342. PubMed ID: 30717648
[TBL] [Abstract][Full Text] [Related]
11. Computational analysis of PKA-balanol interactions.
Wong CF; Hünenberger PH; Akamine P; Narayana N; Diller T; McCammon JA; Taylor S; Xuong NH
J Med Chem; 2001 May; 44(10):1530-9. PubMed ID: 11334563
[TBL] [Abstract][Full Text] [Related]
12. An organoiron approach to the benzophenone appendage of the protein kinase C inhibitor balanol.
Storm JP; Andersson CM
Org Lett; 1999 Nov; 1(9):1451-3. PubMed ID: 10825993
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Account on the Synthesis of (-)-Balanol and its Analogues.
Ahmad S; Akhtar R; Zahoor AF
Curr Org Synth; 2022; 19(1):56-85. PubMed ID: 34370642
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for selective inhibition of human PKG Iα by the balanol-like compound N46.
Qin L; Sankaran B; Aminzai S; Casteel DE; Kim C
J Biol Chem; 2018 Jul; 293(28):10985-10992. PubMed ID: 29769318
[TBL] [Abstract][Full Text] [Related]
16. Molecular Dynamics Pinpoint the Global Fluorine Effect in Balanoid Binding to PKCε and PKA.
Hardianto A; Liu F; Ranganathan S
J Chem Inf Model; 2018 Feb; 58(2):511-519. PubMed ID: 29341608
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development.
Goekjian PG; Jirousek MR
Curr Med Chem; 1999 Sep; 6(9):877-903. PubMed ID: 10495357
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of the potent natural product inhibitor balanol in complex with the catalytic subunit of cAMP-dependent protein kinase.
Narayana N; Diller TC; Koide K; Bunnage ME; Nicolaou KC; Brunton LL; Xuong NH; Ten Eyck LF; Taylor SS
Biochemistry; 1999 Feb; 38(8):2367-76. PubMed ID: 10029530
[TBL] [Abstract][Full Text] [Related]
19. An asymmetric aminohydroxylation approach to the azepine core of (-)-balanol.
Masse CE; Morgan AJ; Panek JS
Org Lett; 2000 Aug; 2(17):2571-3. PubMed ID: 10990399
[TBL] [Abstract][Full Text] [Related]
20. Structure of human G protein-coupled receptor kinase 2 in complex with the kinase inhibitor balanol.
Tesmer JJ; Tesmer VM; Lodowski DT; Steinhagen H; Huber J
J Med Chem; 2010 Feb; 53(4):1867-70. PubMed ID: 20128603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
